{{PBB|geneid=6559}}

'''鈉氯同向轉運體'''({{lang|en|sodium-chloride symporter}}、亦稱為'''鈉氯協同轉運蛋白'''({{lang|en|<u>N</u>a<sup>+</sup>-<u>C</u>l<sup>−</sup> cotransporter}})、簡稱為{{lang|en|NCC}}或{{lang|en|NCCT}}，或'''敏感噻嗪類鈉氯協同轉運蛋白'''({{lang|en|<u>t</u>hiazide-<u>s</u>ensitive Na<sup>+</sup>-Cl<sup>−</sup> <u>c</u>otransporter}})、或簡稱{{lang|en|TSC}}，鈉氯離子同向轉運體)是在腎臟的一個[[協同轉運蛋白|協同轉運蛋白]](cotransporter)其具有再吸收[[鈉|鈉]]及[[氯|氯]][[離子|離子]]的功能，並從[[腎小管液|腎小管液]]進入[[腎|腎]]的[[遠曲小管|遠曲小管]]細胞內。它是"電中性的陽離子結合氯離子的協同轉運蛋白"之[[溶質載體家族|SLC12協同轉運蛋白家族]]的一個成員。在人類中，它是由位於16q13的SLC12A3基因(溶質載體家族12成員的第3)所編碼。<ref name="pmid8812482">{{cite journal | author = Mastroianni N, De Fusco M, Zollo M, Arrigo G, Zuffardi O, Bettinelli A, Ballabio A, Casari G | title = Molecular cloning, expression pattern, and chromosomal localization of the human Na-Cl thiazide-sensitive cotransporter (SLC12A3) | journal = Genomics | volume = 35 | issue = 3 | pages = 486–93 |date=August 1996 | pmid = 8812482 | doi = 10.1006/geno.1996.0388| url =  }}</ref>

==分子生物學==
鈉氯同向轉運體或NCC是"電中性的陽離子結合氯離子的協同轉運蛋白"之SLC12協同轉運蛋白家族的一員，伴隨著[[鈉鉀氯共轉運蛋白|鉀氯共轉運蛋白]](K<sup>+</sup>-Cl<sup>−</sup>協同轉運蛋白或KCCs)、[[鈉鉀氯共轉運蛋白|鈉鉀氯共轉運蛋白]](Na<sup>+</sup>-K<sup>+</sup>-Cl<sup>−</sup>協同轉運蛋白或NKCCs)及孤兒成員CIP([[SLC12A9|協同轉運蛋白相互作用蛋白]])與[[SLC12A8|CCC9]]。<!--The sodium-chloride symporter's [[protein_sequence|protein sequence]] has a high degree of identity between different [[mammal|mammalian species]] (over 90% between human, rat and mouse). The ''SLC12A3'' [[gene|gene]] encodes for a [[protein|protein]] of 1,002 to 1,030 [[amino_acid|amino acid]] residues. NCC is a [[transmembrane_protein|transmembrane protein]], presumed to have a [[hydrophobicity|hydrophobic core]] of either 10 or 12 [[transmembrane_helix|transmembrane domains]] with intracellular [[N-terminus|amino-]] and [[C-terminus|carboxyl-terminus]] domains. The exact structure of the NCC protein is unknown, as it has not yet been [[protein_crystallization|crystallized]]. The NCC protein forms [[protein_dimer|homodimers]] at the plasma membrane.

[[N-linked_glycosylation|N-glycosylation]] occurs in two sites in a long extracellular loop connecting two transmembrane domains within the hydrophobic core. This [[posttranslational_modification|posttranslational modification]] is necessary for proper folding and transport of the protein to the [[plasma_membrane|plasma membrane]].<ref name="pmid19474192">{{cite journal | author = Gamba G | title = The thiazide-sensitive Na<sup>+</sup>-Cl<sup>−</sup> cotransporter: molecular biology, functional properties, and regulation by WNKs. | journal = American Journal of Physiology Renal Physiology| volume = 297 | issue = 4 | pages = F838–48 |date=May 2009| doi = 10.1152/ajprenal.00159.2009 | pmid = 19474192 | pmc = 3350128}}</ref>-->

==功能==<!--
Because NCC is located at the [[Epithelial_polarity#Apical_membranes|apical membrane]] of the distal convoluted tubule of the nephron, it faces the [[Lumen_(anatomy)|lumen of the tubule]] and is in contact with the tubular fluid. Using the [[Na+/K+-ATPase#Transport|sodium gradient]] across the apical membrane of the cells in distal convoluted tubule, the sodium-chloride symporter transports Na<sup>+</sup> and Cl<sup>−</sup> from the tubular fluid into these cells. Afterward, the Na<sup>+</sup> is pumped out of the cell and into the bloodstream by the Na<sup>+</sup>-K<sup>+</sup> ATPase located at the [[Epithelial_polarity#Basolateral_membranes|basal membrane]] and the Cl<sup>−</sup> leaves the cells through the basolateral [[CLCNKB|chloride channel ClC-Kb]]. The sodium-chloride symporter accounts for the absorption of 5% of the salt filtered at the [[glomerulus|glomerulus]]. NCC activity is known to have two control mechanisms affecting protein trafficking to the plasma membrane and transporter kinetics by [[phosphorylation|phosphorylation and de-phosphorylation]] of conserved serine/threonine residues.

As NCC has to be at the plasma membrane to function, its activity can be regulated by increasing or decreasing the amount of protein at the plasma membrane. Some NCC modulators, such as the [[WNK3|WNK3]] and [[WNK4|WNK4]] kinases may regulate the amount of NCC at the cell surface by inducing the insertion or removal, respectively, of the protein from the plasma membrane.<ref name="pmid16275913">{{cite journal | author = Rinehart J, Kahle K, de los Heros P, Vazquez N, Meade P, Wilson F, Hebert S, Gimenez I, Gamba G, Lifton R | title = WNK3 kinase is a positive regulator of NKCC2 and NCC, renal cation-Cl<sup>−</sup> cotransporters required for normal blood pressure homeostasis | journal = PNAS | volume = 102 | issue = 46 | pages = 16777–16782 |date=November 2005 | doi = 10.1073/pnas.0508303102 | pmc = 1283841 | pmid = 16275913}}</ref><ref name="pmid19875813">{{cite journal | author = Zhou B, Zhuang J, Gu D, Wang H, Cebotaru L, Guggino W, Cai H | title = WNK4 Enhances the Degradation of NCC through a Sortilin-Mediated Lysosomal Pathway | journal = Journal of the American Society of Nephrology | volume = 21 | issue = 1 | pages = 82–92 |date=January 2010 | doi = 10.1681/ASN.2008121275 | pmc = 2799281 | pmid = 19875813}}</ref>

Furthermore, many residues of NCC can be phosphorylated or dephosphorylated to activate or inhibit NCC uptake of Na<sup>+</sup> and Cl<sup>−</sup>. Other NCC modulators, including intracellular chloride depletion, [[angiotensin_II|angiotensin II]], [[aldosterone|aldosterone]] and [[vasopressin|vasopressin]], can regulate NCC activity by phosphorylating conserved serine/threonine residues.<ref name="pmid16887815">{{cite journal | author = Pacheco-Alvarez D, San Cristóbal P, Meade P, Moreno E, Vazquez N, Muñoz E, Díaz A, Juárez ME, Giménez I, Gamba G | title = The Na<sup>+</sup>:Cl<sup>−</sup> Cotransporter Is Activated and Phosphorylated at the Amino-terminal Domain upon Intracellular Chloride Depletion | journal = J. Biol. Chem. | volume = 281 | issue = 39 | pages = 28755–28763 |date=August 2006| doi = 10.1074/jbc.M603773200| pmid = 16887815}}</ref><ref name="pmid20720527">{{cite journal | author = van der Lubbe N, Lim C, Fenton R, Meima M, Jan Danser A, Zietse R, Hoorn E | title = Angiotensin II induces phosphorylation of the thiazide-sensitive sodium chloride cotransporter independent of aldosterone| journal = Kidney International| volume = 79 | issue = 1 | pages = 66–76 |date=August 2010 | doi = 10.1038/ki.2010.290 | pmid = 20720527}}</ref><ref name="pmid20445498">{{cite journal | author = Pedersen NB, Hofmeister MV, Rosenbaek LL, Nielsen J, Fenton RA | title = Vasopressin induces phosphorylation of the thiazide-sensitive sodium chloride cotransporter in the distal convoluted tubule| url = https://archive.org/details/sim_kidney-international_2010-07_78_2/page/160 | journal = Kidney International | volume = 78 | issue = 2 | pages = 160–169 |date=July 2010 | doi = 10.1038/ki.2010.130 | pmid = 20445498}}</ref> NCC activity can be inhibited by [[thiazide|thiazide]]s, which is why this symporter is also known as the thiazide-sensitive Na<sup>+</sup>-Cl<sup>−</sup> cotransporter.<ref name="pmid8812482"/>-->

==病理==
===吉特曼氏綜合症 ===<!--
A loss of NCC function is associated with [[Gitelman_syndrome|Gitelman syndrome]], an autosomic recessive disease characterized by salt wasting and low blood pressure, hypokalemic metabolic alkalosis, hypomagnesemia and hypocalciuria.<ref name="pmid18667063">{{cite journal | author = Knoers NV, Levtchenko EN | title = Gitelman syndrome | journal = Orphanet J Rare Dis | volume = 3 | issue = | pages = 22 | year = 2008 | pmid = 18667063 | pmc = 2518128 | doi = 10.1186/1750-1172-3-22 | url =  }}</ref>

Over a hundred different mutations in the NCC gene have been described as causing Gitelman syndrome, including [[nonsense_mutation|nonsense]], [[Frameshift_mutation|frameshift]], [[splice_site_mutation|splice site]] and [[missense_mutation|missense mutation]]s. Two different types of mutations exist within the group of missense mutations causing loss of NCC function. Type I mutations cause a complete loss of NCC function, in which the synthesized protein is not properly glycosylated. NCC protein harboring type I mutations is retained in the endoplasmic reticulum and cannot be trafficked to the cell surface.<ref name="pmid12039972">{{cite journal | author = de Jong JC, can der Vliet WA, van den Heuvel LPWJ, Willems PHGM, Knoers NVAM, Bindels RJM | title = Functional Expression of Mutations in the Human NaCl Cotransporter: Evidence for Impaired Routing Mechanisms in Gitelman's Syndrome |journal = JASN| volume = 13| issue = 6| pages = 1442–1448 | year = 2002 | pmid = 12039972 | doi = 10.1097/01.ASN.0000017904.77985.03 | url =  }}</ref> Type II mutations cause a partial loss of NCC function in which the cotransporter is trafficked to the cell surface but has an impaired insertion in the plasma membrane. NCC harboring type II mutations have normal kinetic properties but are present in lower amounts at the cell surface, resulting in a decreased uptake of sodium and chloride.<ref name="pmid15068971">{{cite journal | author = Sabath E, Meade P, Berkman J, de los Heros P, Moreno E, Bobadilla NA, Vázquez N, Ellison DH, Gamba G | title = Pathophysiology of functional mutations of the thiazide-sensitive Na-Cl cotransporter in Gitelman disease |journal = Am J Physiol Renal Physiol | volume = 287 | issue = 2| pages = F195–F203 | year = 2004 | pmid = 15068971 | doi=10.1152/ajprenal.00044.2004| url = }}</ref> NCC harboring type II mutations is still under control of its modulators and can still increase or decrease its activity in response to stimuli, whereas type I mutations cause a complete loss of function and regulation of the cotransporter.<ref name="pmid21157372">{{cite journal | author = Acuña R, Martínez de la Maza L, Ponce-Coria J, Vázquez N, Ortal-Vite P, Pacheco-Alvarez D, Bobadilla NA, Gamba G|title = Rare mutations in SLC12A1 and SLC12A3 protect against hypertension by reducing the activity of renal salt cotransporters|journal = J Hypertension | pages = 475–83 |year = 2009 | pmid = 21157372 |doi = 10.1097/HJH.0b013e328341d0fd| url = | volume = 29 | issue = 3}}</ref> However, in some patients with Gitelman's syndrome, no mutations in the NCC gene have been found despite extensive genetic work-up.-->

===高血壓及血壓===<!--
NCC has also been implicated to play a role in control of [[blood_pressure|blood pressure]] in the open population, with both common polymorphisms and rare mutations altering NCC function, renal salt reabsorption and, presumably, blood pressure. Individuals with rare mutations in genes responsible for salt control in the kidney, including NCC, have been found to have a lower blood pressure than [[scientific_control|controls]].<ref name="pmid18391953">{{cite journal | author = Weizhen Ji, Jia Nee Foo, Brian J O'Roak, Hongyu Zhao, Martin G Larson, David B Simon, Christopher Newton-Cheh, Matthew W State, Daniel Levy and Richard P Lifton | title = Rare independent mutations in renal salt handling genes contribute to blood pressure variation | journal = Nature Genetics| volume = 40 | issue = 5 | pages = 592–599 | year =2008 | pmid = 18391953 | doi = 10.1038/ng.118 | pmc = 3766631 }}</ref> NCC harboring these mutations has a lower function than [[wild-type|wild-type]] cotransporter although some mutations found in individuals in the open population seem to be less deleterious to cotransporter function than mutations in individuals with Gitelman's syndrome.<ref name=" pmid21157372"/>

Furthermore, heterozygous [[genetic_carrier|carriers]] of mutations causing Gitelman syndrome (i.e. individuals who have a mutation in one of the two [[allele|allele]]s and do not have the disease) have a lower blood pressure than non-carriers in the same family.<ref name="pmid17981812">{{cite journal | author = Fava C, Montagnana M, Rosberg L, Burri P, Almgren P, Jönsson A, Wanby P, Lippi G, Minuz P, Hulthèn G, Aurell M, Melander O | title = Subjects heterozygous for genetic loss of function of the thiazide-sensitive cotransporter have reduced blood pressure | journal = Hum. Mol. Genet.| volume = 17 | issue = 3 | pages = 413–18 | year =2008 | pmid = 17981812 | doi = 10.1093/hmg/ddm318 | url =  }}</ref>-->

===假性醛固酮減少症II型===<!--
[[pseudohypoaldosteronism|Type II pseudohypoaldosteronism]] (PHA2), also known as Gordon's syndrome, is an autosomal dominant disease in which there is an increase in NCC activity leading to short stature, [[hypertension|increased blood pressure]], [[hyperkalemia|increased serum K<sup>+</sup> levels]], [[hypercalciuria|increased urinary calcium excretion]] and hyperchloremic metabolic acidosis. However, PHA2 is not caused by [[mutation|mutation]]s within the NCC gene, but by mutations in NCC regulators [[WNK1|WNK1]] and [[WNK4|WNK4]]. Patients respond well to treatment with thiazide-type diuretics.-->

==參見==
* [[腎單位|腎單位]]
* [[遠曲小管|遠曲小管]](Distal convoluted tubule)
* [[电解质|电解质]]，如[[钠|钠]]及[[氯化物|氯化物]]
*[[協同轉運蛋白|協同轉運蛋白]](Cotransporter)，包括[[同向轉運體|同向轉運體]](symporter)
*[[血壓|血壓]]
* [[利尿劑|利尿劑]]及[[噻嗪類|噻嗪類]](thiazide)

==註釋==
{{Reflist | 2}}

==延伸閱讀==
{{refbegin | 2}}
*{{cite journal |author=Kamdem LK, Hamilton L, Cheng C, ''et al.'' |title=Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia |journal=Pharmacogenet. Genomics |volume=18 |issue= 6 |pages= 507–14 |year= 2008 |pmid= 18496130 |doi= 10.1097/FPC.0b013e3282fc5801 }}
*{{cite journal |author=Coto E, Arriba G, GarcÃa-Castro M, ''et al.'' |title=Clinical and analytical findings in Gitelman's syndrome associated with homozygosity for the c.1925 G>A SLC12A3 mutation |journal=Am. J. Nephrol. |volume=30 |issue= 3 |pages= 218–21 |year= 2009 |pmid= 19420906 |doi= 10.1159/000218104 }}
*{{cite journal |author=Yasujima M, Tsutaya S |title=[Mutational analysis of a thiazide-sensitive Na-Cl cotransporter (SLC12A3) gene in a Japanese population—the Iwaki Health Promotion Project] |journal=Rinsho Byori |volume=57 |issue= 4 |pages= 391–6 |year= 2009 |pmid= 19489442 |doi= }}
*{{cite journal |author=Shao L, Liu L, Miao Z, ''et al.'' |title=A novel SLC12A3 splicing mutation skipping of two exons and preliminary screening for alternative splice variants in human kidney |journal=Am. J. Nephrol. |volume=28 |issue= 6 |pages= 900–7 |year= 2008 |pmid= 18580052 |doi= 10.1159/000141932 }}
*{{cite journal |author=van Rijn-Bikker PC, Mairuhu G, van Montfrans GA, ''et al.'' |title=Genetic factors are relevant and independent determinants of antihypertensive drug effects in a multiracial population |url=https://archive.org/details/sim_american-journal-of-hypertension_2009-12_22_12/page/1295 |journal=Am. J. Hypertens. |volume=22 |issue= 12 |pages= 1295–302 |year= 2009 |pmid= 19779464 |doi= 10.1038/ajh.2009.192 }}
*{{cite journal |author=Shao L, Ren H, Wang W, ''et al.'' |title=Novel SLC12A3 mutations in Chinese patients with Gitelman's syndrome |journal=Nephron Physiol |volume=108 |issue= 3 |pages= p29–36 |year= 2008 |pmid= 18287808 |doi= 10.1159/000117815 }}
*{{cite journal |author=Ji W, Foo JN, O'Roak BJ, ''et al.'' |title=Rare independent mutations in renal salt handling genes contribute to blood pressure variation |journal=Nat. Genet. |volume=40 |issue= 5 |pages= 592–9 |year= 2008 |pmid= 18391953 |doi= 10.1038/ng.118 |pmc=3766631 }}
*{{cite journal |author=Riveira-Munoz E, Devuyst O, Belge H, ''et al.'' |title=Evaluating PVALB as a candidate gene for SLC12A3-negative cases of Gitelman's syndrome |journal=Nephrol. Dial. Transplant. |volume=23 |issue= 10 |pages= 3120–5 |year= 2008 |pmid= 18469313 |doi= 10.1093/ndt/gfn229 }}
*{{cite journal |author=Zhou B, Zhuang J, Gu D, ''et al.'' |title=WNK4 enhances the degradation of NCC through a sortilin-mediated lysosomal pathway |journal=J. Am. Soc. Nephrol. |volume=21 |issue= 1 |pages= 82–92 |year= 2010 |pmid= 19875813 |pmc=2799281 |doi= 10.1681/ASN.2008121275 }}
*{{cite journal |author=Hsu YJ, Yang SS, Chu NF, ''et al.'' |title=Heterozygous mutations of the sodium chloride cotransporter in Chinese children: prevalence and association with blood pressure |journal=Nephrol. Dial. Transplant. |volume=24 |issue= 4 |pages= 1170–5 |year= 2009 |pmid= 19033254 |doi= 10.1093/ndt/gfn619 }}
*{{cite journal |author=Nozu K, Iijima K, Nozu Y, ''et al.'' |title=A deep intronic mutation in the SLC12A3 gene leads to Gitelman syndrome |journal=Pediatr. Res. |volume=66 |issue= 5 |pages= 590–3 |year= 2009 |pmid= 19668106 |doi= 10.1203/PDR.0b013e3181b9b4d3 }}
*{{cite journal |author=Ng DP, Nurbaya S, Choo S, ''et al.'' |title=Genetic variation at the SLC12A3 locus is unlikely to explain risk for advanced diabetic nephropathy in Caucasians with type 2 diabetes |journal=Nephrol. Dial. Transplant. |volume=23 |issue= 7 |pages= 2260–4 |year= 2008 |pmid= 18263927 |doi= 10.1093/ndt/gfm946 }}
*{{cite journal |author=Aoi N, Nakayama T, Sato N, ''et al.'' |title=Case-control study of the role of the Gitelman's syndrome gene in essential hypertension |journal=Endocr. J. |volume=55 |issue= 2 |pages= 305–10 |year= 2008 |pmid= 18362449 |doi=10.1507/endocrj.K07E-021 }}
*{{cite journal |author=Qin L, Shao L, Ren H, ''et al.'' |title=Identification of five novel variants in the thiazide-sensitive NaCl co-transporter gene in Chinese patients with Gitelman syndrome |journal=Nephrology (Carlton) |volume=14 |issue= 1 |pages= 52–8 |year= 2009 |pmid= 19207868 |doi= 10.1111/j.1440-1797.2008.01042.x }}
*{{cite journal |author=Ridker PM, ParÃ© G, Parker AN, ''et al.'' |title=Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study |journal=Circ Cardiovasc Genet |volume=2 |issue= 1 |pages= 26–33 |year= 2009 |pmid= 20031564 |pmc=2729193 |doi= 10.1161/CIRCGENETICS.108.817304 }}
*{{cite journal |author=Richardson C, Rafiqi FH, Karlsson HK, ''et al.'' |title=Activation of the thiazide-sensitive Na<sup>+</sup>-Cl<sup>−</sup> cotransporter by the WNK-regulated kinases SPAK and OSR1 |journal=J. Cell. Sci. |volume=121 |issue= Pt 5 |pages= 675–84 |year= 2008 |pmid= 18270262 |doi= 10.1242/jcs.025312 }}
*{{cite journal |author=Wang XF, Lin RY, Wang SZ, ''et al.'' |title=Association study of variants in two ion-channel genes (TSC and CLCNKB) and hypertension in two ethnic groups in Northwest China |journal=Clin. Chim. Acta |volume=388 |issue= 1–2 |pages= 95–8 |year= 2008 |pmid= 17997379 |doi= 10.1016/j.cca.2007.10.017 }}
*{{cite journal |author=Miao Z, Gao Y, Bindels RJ, ''et al.'' |title=Coexistence of normotensive primary aldosteronism in two patients with Gitelman's syndrome and novel thiazide-sensitive Na–Cl cotransporter mutations |journal=Eur. J. Endocrinol. |volume=161 |issue= 2 |pages= 275–83 |year= 2009 |pmid= 19451210 |doi= 10.1530/EJE-09-0271 }}
*{{cite journal |author=Zhan YY, Jiang X, Lin G, ''et al.'' |title=[Association of thiazide-sensitive Na<sup>+</sup>-Cl* cotransporter gene polymorphisms with the risk of essential hypertension] |journal=Zhonghua Yi Xue Yi Chuan Xue Za Zhi |volume=24 |issue= 6 |pages= 703–5 |year= 2007 |pmid= 18067089 |doi= }}
{{refend}}

==外部連結==
* {{MeshName|Sodium+Chloride+Symporters}}
* {{MeshName|Sodium+Chloride+Symporter+Inhibitors}}

{{ATPase}}
{{Solute carrier family}}

[[Category:溶质载体家族|Category:溶质载体家族]]